Drug Profile
Omburtamab I-124 - Y-mAbs Therapeutics
Alternative Names: 124I-8H9; 124I-8H9 (B7-H3)Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Diffuse intrinsic pontine glioma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(In adolescents, In children, Second-line therapy or greater, In adults) in USA (Intratumoural, Infusion)
- 31 Dec 2023 Suspended - Phase-I for Diffuse intrinsic pontine glioma (In adolescents, In children, Second-line therapy or greater, In adults) in USA (Intratumoural)
- 27 May 2022 Y-mAbs Therapeutics in collaboration with Memorial Sloan Kettering Cancer Center completes a phase I trial in Diffuse intrinsic pontine glioma (In children, In adolescents, In adults, Second-line therapy or greater) in USA (NCT01502917)